Results 41 to 50 of about 11,641 (246)

Genetic polymorphisms of CYP2C9 and CYP2C19 are not related to drug‐induced idiosyncratic liver injury (DILI) [PDF]

British Journal of Pharmacology, 2007
Background and purpose:The general view on the pathogenesis of drug‐induced idiosyncratic liver injury (DILI) is that parent compounds are rendered hepatotoxic by metabolism, mainly by cytochrome (CYP) 450, although other metabolic pathways can contribute. Anecdotal reports suggest a role of CYP 450 polymorphisms in DILI. We aimed to assess in a series
Ketevan Pachkoria, M. Isabel Lucena, Francisco Ruíz-Cabello, Esperanza Crespo, M.R. Cabello, Raúl J. Andrade   +5 more
openalex   +6 more sources

Case of Ibuprofen-Induced Liver Injury

Annals of Internal Medicine: Clinical Cases, 2023
Drug-induced liver injury (DILI) resulting from nonsteroidal anti-inflammatory drugs (NSAIDs) is a rare phenomenon; however, several cases have been reported in the literature and the LiverTox database.
Kirsten Wong, Beda Cha, Simon Wu
doaj   +1 more source

Tandem mass tag-based quantitative proteomic profiling identifies candidate serum biomarkers of drug-induced liver injury in humans

Nature Communications, 2023
Diagnosis of rare, unpredictable, drug-induced liver injury (DILI) is a significant challenge for patients, clinicians, and drug development. Here, the authors discover, evaluate, and validate potential blood biomarkers to diagnose DILI and distinguish ...
Kodihalli C. Ravindra, Vishal S. Vaidya, Zhenyu Wang, Joel D. Federspiel, Richard Virgen-Slane, Robert A. Everley, Jane I. Grove, Camilla Stephens, Mireia F. Ocana, Mercedes Robles-Díaz, M. Isabel Lucena, Raul J. Andrade, Edmond Atallah, Alexander L. Gerbes, Sabine Weber, Helena Cortez-Pinto, Andrew J. Fowell, Hyder Hussaini, Einar S. Bjornsson, Janisha Patel, Guido Stirnimann, Sumita Verma, Ahmed M. Elsharkawy, William J. H. Griffiths, Craig Hyde, James W. Dear, Guruprasad P. Aithal, Shashi K. Ramaiah   +27 more
doaj   +1 more source

The Liver Toxicity Knowledge Base (LKTB) and drug-induced liver injury (DILI) classification for assessment of human liver injury [PDF]

Expert Review of Gastroenterology & Hepatology, 2017
Drug-induced liver injury (DILI) is challenging for drug development, clinical practice and regulation. The Liver Toxicity Knowledge Base (LTKB) provides essential data for DILI study. Areas covered: The LTKB provided various types of data that can be used to assess and predict DILI.
Shraddha Thakkar, Minjun Chen, Hong Fang, Zhichao Liu, Ruth Roberts, Weida Tong   +5 more
openalex   +4 more sources

Combinatorial targeting of G‐protein‐coupled bile acid receptor 1 and cysteinyl leukotriene receptor 1 reveals a mechanistic role for bile acids and leukotrienes in drug‐induced liver injury

Hepatology, EarlyView., 2022
CHIN117 is a dual cysteinyl leukotriene receptor 1 (CYSLTR1) antagonist and G‐protein‐coupled bile acid receptor 1 (GPBAR1) agonist. In the liver, GPBAR1 and CYSLTR1 are coexpressed by liver sinusoidal endothelial cells (LSECs), HSCs, circulating monocytes/macrophages, and liver resident macrophages (Kupffer cells).
Michele Biagioli, Silvia Marchianò, Cristina di Giorgio, Rosalinda Roselli, Martina Bordoni, Rachele Bellini, Bianca Fiorillo, Valentina Sepe, Bruno Catalanotti, Chiara Cassiano, Maria Chiara Monti, Eleonora Distrutti, Angela Zampella, Stefano Fiorucci   +13 more
wiley   +1 more source

Endoplasmic Reticulum Stress and Mitochondrial Stress in Drug-Induced Liver Injury

Molecules, 2023
Drug-induced liver injury (DILI) is a widespread and harmful disease closely linked to mitochondrial and endoplasmic reticulum stress (ERS). Globally, severe drug-induced hepatitis, cirrhosis, and liver cancer are the primary causes of liver-related ...
Sisi Pu, Yangyang Pan, Qian Zhang, Ting You, Tao Yue, Yuxing Zhang, Meng Wang   +6 more
doaj   +1 more source

Identifying Drug-Induced Liver Injury Associated With Inflammation-Drug and Drug-Drug Interactions in Pharmacologic Treatments for COVID-19 by Bioinformatics and System Biology Analyses: The Role of Pregnane X Receptor

Frontiers in Pharmacology, 2022
Of the patients infected with coronavirus disease 2019 (COVID-19), approximately 14–53% developed liver injury resulting in poor outcomes. Drug-induced liver injury (DILI) is the primary cause of liver injury in COVID-19 patients.
Jingjing Huang, Zhaokang Zhang, Chenxia Hao, Chenxia Hao, Yuzhen Qiu, Ruoming Tan, Jialin Liu, Xiaoli Wang, Wanhua Yang, Hongping Qu   +9 more
doaj   +1 more source

Computational Approaches for Drug-Induced Liver Injury (DILI) Prediction: State of the Art and Challenges [PDF]

, 2021
Drug-induced liver injury (DILI) is one of the prevailing causes of fulminant hepatic failure. It is estimated that three idiosyncratic drug reactions out of four result in liver transplantation or death. Additionally, DILI is the most common reason for withdrawal of an approved drug from the market.
Béquignon, O.J.M., Pawara, G., Water, B. van de, Cronin, M.T.D., Westen, G.J.P. van   +4 more
openaire   +2 more sources

Indigenous Herbal Drug (Tinospora Cordifolia) Induced Liver Injury: A Case Report [PDF]

Bengal Physician Journal
Drug-induced liver injury (DILI) is a condition characterized by acute or chronic liver damage following the use of hepatotoxic drugs. It can be classified based on clinical presentation (hepatocellular, cholestasis, or mixed), mechanism of ...
Sounak Kumar Roy, Muniruddin SK, Subham Mondal, Sandipan Mukherjee, Santa Subhra Chatterjee   +4 more
doaj   +1 more source

AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury

, 2022
Hepatology, EarlyView.
Robert J. Fontana, Iris Liou, Adrian Reuben, Ayako Suzuki, M. Isabel Fiel, William Lee, Victor Navarro   +6 more
wiley   +1 more source